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Introduction
With 9.4 million new cases and 1.7
million deaths worldwide in 2009, tuber-
culosis (TB) constitutes an unacceptable
burden of human suffering and loss [1].
The tools available for TB control are old,
lack effectiveness, and are not readily
accessible in many settings: the diagnosis
of pulmonary TB still relies in most high-
burden countries on sputum microscopy, a
century old technology; treatment of
tuberculosis is based on drugs that are
over 40 years old and requires direct
supervision to ensure full treatment adher-
ence and prevent drug resistance; and the
only TB vaccine (BCG), first used in 1922,
has a variable protective efficacy in adults.
Novel tools are needed for better TB care
and control worldwide [2].
Research has a key role to play in
meeting health and development goals.
Based on the World Health Organiza-
tion’s (WHO) Stop TB Strategy, the Stop
TB Partnership has developed the Global
Plan to Stop TB 2011–2015, which lays
out the activities to be achieved by 2015
towards elimination of TB (defined as #1
TB case per million population per year)
by 2050 [3]. The plan sets out a roadmap
for halving TB prevalence and deaths
globally by 2015, compared with 1990
levels. However, while it is estimated that
the incidence rate of TB has been falling
globally since 2004, the present rate of
decline (less than 1% per year) is insuffi-
cient to reach the elimination goal by 2050
[1]. Any realistic prospect of achieving this
goal depends both on the better and wider
use of existing technologies and the
development of revolutionary new tech-
nologies for TB control. This would be
possible only through an acceleration of
research across the continuum, from basic
to implementation [4].
Recognizing this, the Stop TB Partner-
ship and the WHO Stop TB Department
have launched the TB Research Movement,
with the aim of boosting TB research and
accelerating progress in TB control to-
wards international targets [5,6]. We
describe here the strategy developed to
address the objectives (Box 1) of the Re-
search Movement and the progress made
over the last 2 years.
The Research Movement
Strategic Plan
The TB Research Movement is based
at the Stop TB Partnership secretariat,
housed by the WHO in Geneva, and
works in close collaboration with the
WHO Stop TB Department and with
the Working Groups of the Stop TB
Partnership. It operates as an umbrella
for research-related issues at the Partner-
ship, and receives advice from the Part-
nership Coordinating Board and the
WHO.
The strategy plan developed to address
the main objectives of the Research
Movement has two major components:
(1) the analysis of global TB research funding
(aimed at estimating the funding gap); and
(2) the development of a global TB research
roadmap (representing a consensus on global
needs across the TB research spectrum).
To this end, the Research Movement has
mobilized a broad alliance of stakeholders
involved in TB research and development,
including scientists involved in basic, app-
lied, and operational research, TB control
managers and public health officers, do-
nors and aid agencies, and patients and
community representatives.
Analysis of Global TB Research
Funding
Mapping the research funding environ-
ment involves answering the questions
‘‘who is funding TB research and development
(R&D)?’’, ‘‘what is being funded?’’, and ‘‘how
much is being granted?’’. For this, the
Research Movement has joined with the
Treatment Action Group’s (TAG) efforts
in evaluating the global landscape of
funding in TB R&D, through a worldwide
survey of funders and donors. This survey
has been carried out regularly since 2005
and brings elements of responses to the
questions above and helps monitor the
trends in funding TB R&D internationally
[7] (Figure 1).
The revised Global Plan to Stop TB
2011–2015 estimates that at least US$9.8
billion are needed in TB R&D over the
next 5 years to reach the targets of 50%
reduction in TB prevalence and mortality
by 2015, more than twice those estimated
in the initial Global Plan to Stop TB
2006–2015 (Table 1) [8]. Importantly, this
updated Global Plan includes target in-
vestments for fundamental and operational
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diagnostics, and vaccines.
From the above, the research funding gap
can be estimated by comparing the results
of the R&D funding survey to the research
needs outlined in the Global Plan to Stop
TB 2011–2015. Based on TAG Report
2010 [7], assuming that 2009 funding
estimates are maintained throughout
2011–2015, and adjusting for inflation,
the total funding gap for the next 5 years
(2011–2015) is estimated at US$6.4 billion
(64%) (Figure 2). The biggest gap in
absolute terms is in R&D of new drugs,
but the largest in relative terms (as a
percentage of total funding required for
that component) is R&D of new diagnos-
tics. Remarkably, despite a significant
boost in funding R&D for new tools in
the past few years, TB research globally
remains grossly underfunded, with a
funding gap that is disproportionately
greater for TB research (60%) than for
implementation (35%) (Table 2).
The Global TB Research Roadmap
In compiling a global TB research
agenda, the fundamental question is ‘‘what
research is required to stop TB?’’ This involves
answering the questions of ‘‘what are we
researching in TB?’’ and ‘‘are we trying to
answer the right questions?’’, i.e., ‘‘are we doing
studies in areas where evidence is lacking?’’. In
addressing these questions, we needed to
identify critical gaps in research that
represent bottlenecks for development of
new tools. This allowed the development
of a coherent and comprehensive global TB
research roadmap towards TB elimination
that encompasses all aspects of research,
from basic science for discovery, to
development of new tools, and their
optimal uptake for better TB control.
The steps in developing the global TB
research roadmap include a series of
consecutive activities that are described
below: (1) an inventory of the research
Summary Points
N Current tuberculosis (TB) control tools are insufficient to confront the global
burden of TB. Novel tools and interventions are highly needed.
N The Stop TB Partnership and the WHO Stop TB Department have launched the
TB Research Movement, with the aim of boosting TB research and accelerating
progress in TB control towards international targets.
N In this paper, we describe the development of the Research Movement
strategic plan, highlighting progress in its two key components: (1) the analysis
of the global funding landscape for TB research, and (2) the development of a
global TB research agenda.
N Through this strategic plan, the TB research movement is creating a framework
for concrete actions to harmonize and synergize TB research efforts globally, so
that the poor and vulnerable populations burdened by TB will reap the
dividend of less TB through more research and innovation.
Box 1. The TB Research Movement Objectives
Objectives of the Research Movement:
(1) To provide leadership and advocacy to mobilize increased resources in
support of a coherent and comprehensive global TB research agenda to meet
the Stop TB goals and targets; and
(2) To provide a forum for funders and implementers of TB research to coordinate
plans and actions, with the result of ensuring that research needs are
addressed, opportunities identified, and gaps filled.
Figure 1. Investment in TB R&D by research category: 2005–2009 (from TAG report 2010). Reproduced with permission.
doi:10.1371/journal.pmed.1001135.g001
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research questions; and (3) the prioritiza-
tion of research questions.
Inventory of TB research agen-
das. Over the past decade, a variety of
research agendas has been developed by
various groups. A systematic review of
these TB research agendas was carried out
to evaluate the main research questions
and themes, assess the methods used to
select priorities, and identify any consistent
message emerging from these agendas [9].
The review identified 33 papers. The
priority areas for research were: drug
development (28 articles), diagnosis (27),
epidemiology (20), health services research
(16), basic research (13), and vaccine
development (13) (Table 3). Research
questions were usually quite broad in
scope. The most focused questions were
on treatment and prevention of multidrug-
resistant TB and TB/HIV co-infection,
reflecting the inefficiencies of sputum-
smear microscopy and the limits of the
currently recommended short-course che-
motherapy, which is inefficient against
drug-resistant forms of the disease and
is difficult to combine with standard
antiretroviral therapy. The importance of
epidemiology and health system research
probably reflects the need for studies to
optimize the availability and cost-effective-
ness of interventions for TB control. The
relatively low priority assigned to basic
research may indicate the difficulty of
establishing an agenda in a field that is
mostly investigator driven.
The methods used to identify priorities in
these various agendas varied greatly. Most of
these relied on expert meetings with consen-
sus seeking, but few used objectively mea-
surable criteria to select research priorities.
Increased recourse to systematic reviews and
use of clearly described and reproducible
criteria to assess the importance of the
research questions would greatly help in
the establishment of research priorities.
Workshops to identify key research
questions. Four workshops were orga-
nized in 2009 and 2010 to map out the
landscape of TB research and identify gaps
and priorities across the research continuum:
N Two workshops were organized on
new diagnostics, drugs, and vaccines.
These assembled scientists, program
managers, public–private partnerships,
representatives from civil society, do-
nors, and members of the Stop TB
Partnership Working Groups. The
objectives were to review the progress
achieved since 2006 in the Global Plan
to Stop TB 2006–2015, and update
the research activities needed for the
development of new diagnostics, drugs,
and vaccines to meet the targets of the
Global Plan by 2015.
N A workshop on basic research for TB
was organized in Bethesda, Maryland,
United States, in March 2010, with the
support of the National Institutes of
Health/National Institute of Allergy
and Infectious Diseases (NIH/NIAID)
and TAG. The objective was to define
the critical priority questions that need
tobeaddressedinthefundamentalresearch
area to underpin the development of
new drugs, diagnostics and vaccines.
Table 1. Global Plan to Stop TB 2011–
2015: total needs (US$ billion).
Plan Component
Total
Funding
Required
(% Total)
Implementation 36.9 (79%)
- DOTS 22.6 (48%)
- Drug-resistant TB 7.1 (15%)
- TB/HIV 2.8 (6%)
- Laboratory strengthening 4.0 (8%)
- Technical assistance 0.4 (1%)
Research and Development 9.8 (21%)
- Fundamental research 2.1 (5%)
- New diagnostics 1.7 (4%)
- New drugs 3.7 (8%)
- New vaccines 1.9 (4%)
- Operational research 0.4 (1%)
All components 46.7 (100%)
Adapted from reference [3].
doi:10.1371/journal.pmed.1001135.t001
Figure 2. Funding required and available by research component 2011–2015.
doi:10.1371/journal.pmed.1001135.g002
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reiterating the importance of funda-
mental science as the driver of innova-
tion for improved TB control [10].
N A workshop was organized in May 2010
with the support of the Global Fund to
Fight AIDS, Tuberculosis and Malaria
to identify the operational (i.e., imple-
mentation, programmatic) research pri-
orities to improve TB care and control.
Five areas were identified: (i) access to,
screening for, and diagnosis of drug-
susceptible and drug-resistant TB; (ii)
development of sustainable collabora-
tion with all practitioners for TB care
and control; (iii) prevention and treat-
ment of TB in HIV-infected TB pa-
tients; (iv) optimal access to and delivery
of treatment for drug-susceptible and
drug-resistant TB; and (v) capacity
building. Participants developed a list
of operational research questions that
were subsequently circulated to the
Working Groups of the Stop TB
Partnership for comments and sugges-
tions [11]. One of the main outcomes of
the workshop was the development of a
document that lists the research priori-
ties in the five key areas and provides, for
each of these, a synopsis of the relevant
methods and designs to address these
research questions [12].
The prioritization of research ques-
tions. More than 250 research questions
were identified within these workshops in
the areas of fundamental science, R&D of
new diagnostics, drugs, and vaccines, and
operational and public health research.
We set up a prioritization process to rank
these questions using clearly defined and
objectively measurable indicators, adapted
from the Child Health Nutrition Research
Initiative [13]. Prioritization was primarily
based on the value that a scientific question
is adding to the research area, how critical
it is for the development of new tools and
how it provides guidance for the imple-
mentation of these tools, to ultimately
reduce morbidity and mortality due to TB.
The priority ranking process was carried
out independently by a group of 50 multi-
disciplinary stakeholders representing a
wide scope of research areas, public heal-
th, clinical care, and program manage-
ment aspects.
Development of a roadmap for
international TB research towards
elimination. A coherent list of key
research questions to be addressed for
better TB control was established. We
then requested experts to estimate the
timeline under which these key research
questions will be addressed in a chro-
nological sequence, and their feasibility, so
as to assess how the responses to these
questions will fill the knowledge gaps and
be conducive to further questions. The
roadmap for international TB research
is thus a living document that will be
updated according to progress made. It is
expected that the roadmap will provide a
common framework for scientific disci-
plines to work concurrently and colla-
boratively towards better TB control, and
will serve to promote TB research world-
wide, including in high-burden countries.
The roadmap was presented and dis-
cussed at an international strategic meet-
ing held in March 2011 in Bellagio, Italy,
with the co-sponsorship of the Rockefeller
Foundation. This meeting assembled ma-
jor stakeholders, including key scientific
thought leaders, representatives from non-
governmental organizations (NGOs), the
vice ministers of health of Brazil and South
Africa, and the top worldwide investors in
TB research. The aim was to discuss the
roadmap’s vision of harmonized, synergis-
tic, global TB research efforts through
coordination of actions and funding. A
summary of the main conclusions is provi-
ded in Box 2. In short, the Bellagio partici-
pants agreed that the Research Roadmap
was a key vehicle to speed-up and coor-
dinate TB research worldwide and that it
be formally endorsed by the Coordinating
Board of the Stop TB Partnership. It is
expected that the roadmap will serve as a
reference for activities carried out in the
described research areas in support of the
research objectives described in the Global
Plan 2011–2015 and beyond.
Discussion
Devising a creative research response to
the global TB epidemic is a pressing health
research issue. In the context of health and
human development, research to acceler-
ate progress in TB control will have a
direct impact not only on decreasing suf-
fering and saving lives, but also on alle-
viating poverty and promoting social and
economic development.
Much progress has been made over the
last decade in the development of new
tools for better TB control after decades of
neglect. The TB diagnostics pipeline has
rapidly expanded, and a major break-
through was the recent introduction of
Xpert MTB/RIF, a molecular assay
capable of diagnosing TB and the pres-
ence of rifampicin resistance in 100 min-
Table 2. Funding required and funding available under two possible scenarios and
likely funding gaps (US$ billions).
Scenario 1.
Funding maintained
at 2009/2010 levels
a
Scenario 2.
As for Scenario 1, but
domestic funding for
implementation increases
at rate of per capita
income growth
b
IMPLEMENTATION
A. Funding required 37 37
B. Domestic (endemic country) funding available 21 23
- Brazil, China, India, South Africa and Europe 15 17
- Rest of world 5 6
C. External (donor) funding available if
2010 levels maintained
a
33
D. Funding gap (A–B–C) 13 11
RESEARCH AND DEVELOPMENT
E. Funding required 10 10
F. Funding available if 2009 levels maintained
c 33
G. Funding gap (E–F) 6 6
TOTAL FUNDING GAP 19 17
aAdjusted only for inflation.
bGDP per capita in international dollars (purchasing power parity), forecast for the period 2011–2015 by the
International Monetary Fund.
cBased on the TAG report (November 2010), assuming that 2009 levels are maintained throughout 2011–
2015, adjusted only for inflation.
Adapted from reference [3].
doi:10.1371/journal.pmed.1001135.t002
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has substantially expanded with more than
15 compounds in preclinical and clinical
development, including nine novel candi-
dates currently in phase I and II trials [15].
Ten vaccine candidates have entered
clinical trials, four of which are presently
in phase II trials [16]. Through the
commitment of public–private partner-
ships and the engagement of major public
and private research donors, there is a
potential for efficient new tools to be
available before 2015. This is, however,
insufficient. As suggested by a recent
mathematical model, the possibility to
effectively control and eliminate TB by
2050 would rely on the combined and
synergistic implementation of several novel strate-
gies, including improved diagnosis of drug-
susceptible and drug-resistant TB, shorter
treatment of overt TB cases (#2 months),
scaled-up treatment of latently infected
persons (especially in high-risk popula-
tions), and mass vaccinations campaigns
using a more effective vaccine [17]. This
will happen only through synergistic
efforts in all areas of R&D.
This formidable challenge will not be
met without increased investment in
fundamental research for a better under-
standing of the natural history of TB in
humans [3]. Further progress is needed to
develop a point of care diagnostic tool that
would diagnose all forms of TB in all
settings, including latent TB infection [18].
While novel drugs are reaching the late
development phase, we still need to
identify suitable combinations to treat
optimally all forms of TB in all populations
and risk groups, as well as latent TB
infection [19]. Lastly, the search for highly
effective vaccines for the prevention of TB
in all populations needs to be continued
and amplified [16]. For each of these tools,
the development pathway has a high
attrition rate, and the chances of a
successful product emerging from the end
of the development pipeline depend in
large part on the number of potential
products entering the pipeline [19,20].
Research is also needed downstream to
identify means to improve TB control with
existing tools, and guide the uptake and
scale-up of innovations within reinforced
health systems in endemic countries [21].
In this, the WHO plays a crucial norma-
tive role in assessing the evidence to
endorse (or not) the new tool(s) or
intervention(s) and providing guidance on
their implementation through policy rec-
ommendations and technical support.
This process has been conducted recently
for new molecular diagnostics [20], and
needs to be pursued for the new anti-TB
Table 3. Number of studies identifying priority topics for TB research in a systematic
review of 33 articles with TB research priorities.
Research Topic n
Drug development and use (7 or more articles) 28
Chemoprophylaxis effectiveness studies 9
Optimal length of drug treatment—new and old regimes 9
Development of new anti-TB drugs 7
Pharmacokinetics of standard drugs 7
Drug interaction studies (with concomitant antiretroviral use) 7
Pharmakokinetics of second-line drugs 7
Diagnosis and diagnostic tests (8 or more articles) 27
New diagnostic tests for active TB 14
New drug sensitivity testing methods 11
Evaluation of diagnostic pathway for the diagnosis of active TB 8
Biomarkers of successful treatment (for clinical or future trial use) 8
Epidemiology and public health (5 or more articles) 20
Accurate measurement of the global burden of TB disease 8
Determination of the role of social factors within communities on the risk of infection/transmission 5
Effect of treatment literacy programs on adherence and burden of disease 5
Health services research (4 or more articles) 16
Investigation of the causes of diagnostic delay 4
Modeling TB- associated costs/health service requirements 4
Role of patient groups in case finding 4
Best model for integrating TB and HIV services 4
Training requirements for staff providing TB care 4
Basic science research (3 or more articles) 13
Identification of host correlates of protection against TB disease 4
Understanding latent infection and latency 4
Understanding genetic and phenotypic markers of TB resistance 4
Development of an animal model that predicts treatment duration 4
Vaccine development and use (2 or more articles) 13
Development and trials of new TB vaccine 8
Source: Rylance et al. [9].
doi:10.1371/journal.pmed.1001135.t003
Box 2. Conclusions of the Bellagio Meeting (16 March 2011)
The participants at the Bellagio meeting encouraged the Stop TB Partnership to
endorse the Roadmap for International Research to Eliminate TB, publish it
promptly as an independent document, and facilitate the execution of the
following Action Plan:
(1) Elaborate key areas of emphasis from the research roadmap to define an
action plan for global TB research (including research advocacy);
(2) Initiate consultations with countries, especially BRICS countries, researchers,
policy makers, the private sector, and civil society to explore the key areas of
emphasis/action plan and build ownership;
(3) Match existing funded research with areas of emphasis to avoid unnecessary
duplication, leverage existing resources and infrastructure to catalyse more
effective collaborations;
(4) Funders will establish a harmonization and coordination mechanism for
research support.
PLoS Medicine | www.plosmedicine.org 5 November 2011 | Volume 8 | Issue 11 | e1001135drugs that will soon become available [19].
For this to happen smoothly, global
coordination of efforts is essential to ensure
rapid transfer of products and innovations
to endemic countries.
There are, however, major challenges to
be overcome. In view of the current global
economic situation and the likelihood that
available support by current major donors
may stagnate or even decline in the near
future, there is a need to increase the
number and diversity of donors, and make
the most rational use of any dollar spent
on research. Countries with a high TB
burden, especially Brazil, Russia, India,
China, and South Africa (BRICS), could
play a major role in TB R&D through
increased contribution, as exemplified by
the recent declaration from the first
BRICS Health Ministers Summit in Beij-
ing, China, in July 2011 [22,23], which re-
cognized the ‘‘need to establish priorities
in research and development’’ and called
for ‘‘increased innovation’’ in TB, and for
support of ‘‘transfer of technologies and
innovation in a sustainable way’’.
Further discussions are needed so that
key donors in TB research develop a
consensus on funding a harmonized global
TB research agenda for the years to come,
and to enable the much needed accelera-
tion in the development of new tools for
control and their rapid uptake in policy
and practice. This can take the form of
coordinated cross-disciplinary projects to
expedite research in specifically identified
key strategic areas that will lead to con-
crete public health outcomes. It is expect-
ed that the International Roadmap for
Tuberculosis Research will serve as a
framework for concrete actions to syner-
gize TB research efforts globally and ca-
talyze the development of new research
collaborations to address difficult and yet
unanswered questions in TB. The Re-
search Movement can play a crucial role
in leveraging existing resources and infra-
structure to accelerate research for much
needed progress in TB control towards
achievement of international targets [2,3].
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